3 ASX Growth Companies With Insider Ownership Up To 37%

In This Article:

As the Australian market experiences mixed performances across various sectors, with IT and Telecommunications leading gains and Energy facing significant sell-offs, investors are keenly observing growth opportunities within the ASX. In this context, companies with high insider ownership can be particularly appealing as they often indicate strong internal confidence in the business's future prospects.

Top 10 Growth Companies With High Insider Ownership In Australia

Name

Insider Ownership

Earnings Growth

Clinuvel Pharmaceuticals (ASX:CUV)

10.4%

27.4%

Genmin (ASX:GEN)

12%

117.7%

Catalyst Metals (ASX:CYL)

17%

49.1%

Hillgrove Resources (ASX:HGO)

10.4%

71.5%

AVA Risk Group (ASX:AVA)

15.7%

118.8%

Pointerra (ASX:3DP)

20.1%

126.4%

Liontown Resources (ASX:LTR)

14.7%

61%

Acrux (ASX:ACR)

17.4%

91.6%

Adveritas (ASX:AV1)

21.1%

144.2%

Plenti Group (ASX:PLT)

12.8%

106.4%

Click here to see the full list of 99 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Let's dive into some prime choices out of the screener.

Mesoblast

Simply Wall St Growth Rating: ★★★★★☆

Overview: Mesoblast Limited is involved in the development of regenerative medicine products across Australia, the United States, Singapore, and Switzerland, with a market cap of A$1.59 billion.

Operations: The company's revenue is primarily derived from the development of its cell technology platform for commercialization, totaling $5.90 million.

Insider Ownership: 22.2%

Mesoblast is poised for significant growth with its high insider ownership, despite recent financial challenges. The company anticipates becoming profitable within three years and expects revenue to grow at 45.8% annually, outpacing the Australian market. Mesoblast's Ryoncil, a promising therapy for pediatric SR-aGVHD, has received FDA Fast Track and Priority Review designations. Recent developments include a A$72.7 million convertible note issue to support ongoing projects and potential FDA approval by January 2025 could further enhance growth prospects.

ASX:MSB Earnings and Revenue Growth as at Oct 2024
ASX:MSB Earnings and Revenue Growth as at Oct 2024

Pinnacle Investment Management Group

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Pinnacle Investment Management Group Limited is an Australian investment management company with a market capitalization of A$3.79 billion.

Operations: The company generates revenue primarily from its Funds Management Operations, amounting to A$48.99 million.